1.
Alzheimers Dement
; 10(5 Suppl): S395-9, 2014 Oct.
Article
in English
| MEDLINE
| ID: mdl-24418060
ABSTRACT
Florbetapir (18F) for brain amyloid positron emission tomography (PET) imaging has been recently approved in Europe to estimate ß-amyloid neuritic plaque density in the brain when the subject is still alive. Such density is one of the key issues for the definitive diagnosis of Alzheimer's disease (AD) at autopsy. This capability of florbetapir (18F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. The current paper highlights the specific characteristics of the European marketing authorization of florbetapir (18F).
Subject(s)
Aniline Compounds , Brain/diagnostic imaging , Ethylene Glycols , Fluorine Radioisotopes , Plaque, Amyloid/diagnostic imaging , Positron-Emission Tomography/methods , Radiopharmaceuticals , Alzheimer Disease/diagnosis , Alzheimer Disease/diagnostic imaging , Aniline Compounds/adverse effects , Cognition Disorders/diagnosis , Cognition Disorders/diagnostic imaging , Drug Approval , Ethylene Glycols/adverse effects , Europe , Fluorine Radioisotopes/adverse effects , Humans , Positron-Emission Tomography/adverse effects , Radiopharmaceuticals/adverse effects , Risk , Sensitivity and Specificity
2.
Clin Nucl Med
; 32(6): 466-7, 2007 Jun.
Article
in English
| MEDLINE
| ID: mdl-17515757